Cargando…

PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates

Pomalidomide and lenalidomide are immunomodulatory agents that were derived from thalidomide. Cereblon (CRBN) is a common direct target of thalidomide and related compounds and works as a Cullin Ring 4 E3 ubiquitin ligase (CRL4) with DDB1, CUL4, and ROC1. The substrate specificity of CRL4(CRBN) is m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimizu, Nobuyuki, Asatsuma-Okumura, Tomoko, Yamamoto, Junichi, Yamaguchi, Yuki, Handa, Hiroshi, Ito, Takumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586336/ https://www.ncbi.nlm.nih.gov/pubmed/34764413 http://dx.doi.org/10.1038/s42003-021-02801-y

Ejemplares similares

Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide
por: Tateno, Shumpei, et al.
Publicado: (2020)

Thalidomide and its metabolite 5‐hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF
por: Yamanaka, Satoshi, et al.
Publicado: (2021)

Molecular Mechanisms of the Teratogenic Effects of Thalidomide
por: Asatsuma-Okumura, Tomoko, et al.
Publicado: (2020)

Cereblon Control of Zebrafish Brain Size by Regulation of Neural Stem Cell Proliferation
por: Ando, Hideki, et al.
Publicado: (2019)

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN)
por: Gandhi, Anita K, et al.
Publicado: (2014)

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation
por: Yamanaka, Satoshi, et al.
Publicado: (2023)

Profiling the Landscape of Drug Resistance Mutations in Neosubstrates to Molecular Glue Degraders
por: Gosavi, Pallavi M., et al.
Publicado: (2022)

Regulation of AMPK Activity by CRBN Is Independent of the Thalidomide-CRL4(CRBN) Protein Degradation Axis
por: Yang, Seung-Joo, et al.
Publicado: (2021)

Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
por: Bjorklund, C C, et al.
Publicado: (2015)

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
por: Bjorklund, Chad C., et al.
Publicado: (2019)

Shape-shifting and tumor suppression by PLZF
por: Hobbs, Robin M., et al.
Publicado: (2010)

Implication of intracellular localization of transcriptional repressor PLZF in thyroid neoplasms
por: Matsuzawa, Kazuhiko, et al.
Publicado: (2014)

Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4
por: Belair, David G., et al.
Publicado: (2020)

Crbn modulates calcium influx by regulating Orai1 during efferocytosis
por: Moon, Hyunji, et al.
Publicado: (2020)

Population Pharmacokinetics of Pomalidomide
por: Li, Yan, et al.
Publicado: (2015)

Pomalidomide-induced hypothyroidism
por: Ali, Sulaiman Haji, et al.
Publicado: (2017)

Characterisation of Genome-Wide PLZF/RARA Target Genes
por: Spicuglia, Salvatore, et al.
Publicado: (2011)

Role of PLZF as a tumor suppressor in prostate cancer
por: Jin, Yang, et al.
Publicado: (2017)

Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide
por: Fischer, Eric S., et al.
Publicado: (2014)

The Relationship Between the Expression of CRBN in Peripheral Blood and the Severity and Prognosis of Adult Sepsis
por: Kuang, Zhiming, et al.
Publicado: (2023)

Pomalidomide for the Treatment of Multiple Myeloma
por: Clark, Stephen M., et al.
Publicado: (2014)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Identification of DNA-Dependent Protein Kinase Catalytic Subunit (DNA-PKcs) as a Novel Target of Bisphenol A
por: Ito, Yuki, et al.
Publicado: (2012)

Targeting the Acute Promyelocytic Leukemia-Associated Fusion Proteins PML/RARα and PLZF/RARα with Interfering Peptides
por: Beez, Sabine, et al.
Publicado: (2012)

An allele separating skeletal patterning and spermatogonial renewal functions of PLZF
por: Ching, Yung-Hao, et al.
Publicado: (2010)

PLZF limits enhancer activity during hematopoietic progenitor aging
por: Poplineau, Mathilde, et al.
Publicado: (2019)

Identification of EOMES-expressing spermatogonial stem cells and their regulation by PLZF
por: Sharma, Manju, et al.
Publicado: (2019)

Design, Synthesis, and Biological Evaluation of HDAC Degraders with CRBN E3 Ligase Ligands
por: Lu, Yingxin, et al.
Publicado: (2021)

pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase
por: An, Jian, et al.
Publicado: (2017)

PLZF(+) Innate T Cells Support the TGF-β-Dependent Generation of Activated/Memory-Like Regulatory T Cells
por: Kang, Byung Hyun, et al.
Publicado: (2016)

Spotlight on pomalidomide: could less be more?
por: Zander, T, et al.
Publicado: (2017)

De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives
por: Heim, Christopher, et al.
Publicado: (2019)

Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
por: Jones, J. R., et al.
Publicado: (2021)

Gluconeogenic signals regulate hepcidin gene expression via a CRBN-KLF15 axis
por: Jo, Jeong-Rang, et al.
Publicado: (2021)

CRL4(CRBN) E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma
por: Barankiewicz, Joanna, et al.
Publicado: (2022)

Thalidomide Attenuates Mast Cell Activation by Upregulating SHP-1 Signaling and Interfering with the Action of CRBN
por: Chang, Hyeun-Wook, et al.
Publicado: (2023)

PLZF(+) T cells regulate memory-like CD8(+) T cell development
por: Weinreich, Michael A., et al.
Publicado: (2010)

PLZF is a negative regulator of retinoic acid receptor transcriptional activity
por: Martin, Perrine J, et al.
Publicado: (2003)

PLZF Regulates Fibroblast Growth Factor Responsiveness and Maintenance of Neural Progenitors
por: Gaber, Zachary B., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4cecr5lijvv4fae1kj56ljr2q7